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Introduction
Leptomeningeal metastases (LM) occur in 3.4%-3.8% of nonsmall-cell lung cancer (NSCLC) patients, especially in 9.4% of those with an epidermal growth factor receptor (EGFR) mutation [1, 2] . EGFR tyrosine kinase inhibitors (TKIs) markedly prolong survival [3] , but LM remain a devastating complication. Since leptomeningeal lesions are difficult to access, resulting in a poor understanding of the resistance mechanisms of LM, greater efforts have been made to trace the evolution of the tumor genome in accessible body fluids including plasma and cerebrospinal fluid (CSF) [4] [5] [6] [7] [8] [9] .
The circulating cell-free DNA (cfDNA) of plasma has been applied to the prediction of outcomes in NSCLC with dynamic changes of the EGFR status [10] . However, it may play a limited role in detecting cfDNA originating from intracranial lesions [6] . On the other hand, CSF circulates throughout the central nervous system (CNS) and may provide potential information on intracranial lesions. Moreover, selected gene profiles in CSF could be consistent with their primary tumors [4] . Altogether, previous studies indicated that CSF could be an important method of liquid biopsy in patients with CNS cancers. However, only a very limited number of patients with NSCLC were included in these studies, and little is known about the resistance mechanisms of LM in NSCLC harboring EGFR mutations [4] [5] [6] [7] [8] .
The current study provides stronger evidences of the clinical utility of CSF as liquid biopsy medium in LM of EGFR-mutant NSCLC and review the tumor evolution of LM spatiotemporally.
Methods-patients
In total, 45 NSCLC patients with suspected LM underwent lumbar puncture between July 2016 and February 2017 at the Guangdong Lung Cancer Institute. Approximately 10 mL of CSF was collected via lumbar puncture for cytology examination and next-generation sequencing (NGS), and 8 mL of plasma was collected for NGS at the same time. Available primary lung lesions were obtained from the specimen repository.
The diagnosis criteria of LM were a positive result on brain MRI or CSF cytology, or the presence of CSF cfDNA; 28 patients with EGFR mutations diagnosed with LM were enrolled in this cohort. Typical imaging of LM was identified as linear or micronodular pial enhancement in MRI by two experienced radiologists. All patients provided signed informed consent and the study protocol was approved by the Research Ethics Committee of Guangdong General Hospital.
Methods-materials
Preparation of plasma, CSF, and tissue DNA An identical procedure was used for cfDNA extraction from whole blood and CSF, and DNA was extracted using the QIAamp DNA FFPE tissue kit (Qiagen), in accordance with the manufacturer's instructions. Full description was in supplementary Methods, available at Annals of Oncology online.
NGS library preparation and sequencing data analysis
NGS library preparation was carried out in an identical procedure, and sequencing data were mapped to the human genome (hg19) using Burrows-Wheeler aligner 0.7.10. Local alignment optimization, variant calling. Full description was in supplementary Methods, available at Annals of Oncology online.
Fisher's exact test was used in this study, and was carried out using the SPSS for Windows software package (ver. 13.0; SPSS Inc., Chicago, IL).
Results

Characteristics of patients with LM harboring EGFR mutations
In total, 28 patients were diagnosed with LM (Table 1 ). All patients were Chinese and were diagnosed with lung adenocarcinoma. The median age was 54 years old (range 30-80 years) and 16 patients were male. All patients carried EGFR mutations, including 18 patients with exon 19 deletion, 7 patients with L858R, 2 patients with exon 20 insertion, and 1 patient with L861Q. Adenocarcinoma cells were found in the CSF of 18 patients and 19 patients had typical imaging for LM. All 26 patients with available CSF supernatant for NGS showed positivity for cfDNA in CSF. Seventeen patients had a poor Eastern Cooperative Oncology Group performance status (ECOG PS >1) and 25 patients had concurrent brain metastases.
In total, CSF cfDNA, CSF precipitates, and plasma were available in 26 patients, respectively. Among 25 patients diagnosed with LM during TKI therapy, CSF, and plasma of 22 patients were collected when they were first diagnosed with LM, while those of 3 patients (B06, B21, and B37) were obtained after they had received AZD9291 for several months. Of the total number of patients after failure to TKI, the CSF cfDNA and plasma of 23 patients were available for NGS. Three patients did not receive any TKI before LM (Table 1) .
CSF cfDNA was superior to plasma in identifying driver genes EGFR mutations were detected in the CSF cfDNA in 100% (26/ 26) of patients, which were consistent with those identified in the primary tumor by routine clinical methods. However, mutations were detected in 84.6% (22/26) and 73.1% (19/26) of CSF precipitates and plasma, respectively. Moreover, there was a statistically significant difference in the detection rates between CSF cfDNA and plasma (P ¼ 0.01; Figure 1A ).
The average maximum allele fractions (AFs) of CSF cfDNA, CSF precipitates, and plasma were 62%, 13.9%, and 3.5%, respectively. And 92.3% (24/26) patients had much higher AFs detected in CSF cfDNA than the other two samples ( Figure 1B ).
CSF cfDNA revealed the unique genetic profiles of LM Genetic profiles in CSF cfDNA, primary tumor tissue, plasma, and CSF precipitates were compared (Figure 2 ; supplementary Figure S1 , available at Annals of Oncology online). Only a handful of mutations were detected, with EGFR and TP53 being the two most frequently mutated genes in primary tumor (supplementary Figure S1 , available at Annals of Oncology online). 
Multiple copy number variations in CSF cfDNA
A large number of copy number variations (CNVs) were detected in CSF cfDNA, with the majority being unique to CSF cfDNA, which were not identified in primary tissue or plasma ( Figure 2 ; supplementary Figure S1 , available at Annals of Oncology online). When compared with three patients who had not received any TKI before LM, CNVs in patients after TKI failure were more abundant ( Figure 2 ). Among them, MET copy number gain was the most frequent CNV and was identified in 11 patients (11/23, 47.8%), while MET copy number deletion was detected in further 2 patients. KRAS copy number gain was identified in three patients and KRAS copy number deletion was detected in another patient. ERBB2 (HER2) copy number gain was identified in three patients, ALK copy number gain was detected in three patients and BRAF copy number gain was detected in four patients. Other potential metastasis genes were also identified in CSF cfDNA, including 15 patients with MYC, 11 patients with FGFR1, 11 patients with CDKN2A, 8 patients with CDK6, and 6 patients with CDK 4.
TP53 loss of heterozygosity in CSF cfDNA
In our cohort, TP53 LOH was identified in 73.1% (19/26) of CSF cfDNA, which was much higher than in plasma (2/26, 7.7%; P < 0.001) ( Figure 3A and F) .
Furthermore, LM patients with TP53 LOH were likely to harbor more complicated mechanisms in CSF. Among patients who failed TKI therapy, 12 patients (12/17, 70.6%) with TP53 LOH in CSF cfDNA harbored concomitant resistance mutations (2 resistance genes or more, excluding TP53), while in patients without TP53 LOH, only 2 patients (2/6, 33.3%; P ¼ 0.162) harbored such mutations ( Figure 3B) .
Moreover, EGFR T790M and MET detection rates in the CSF cfDNA of patients with TP53 LOH were slightly higher than those without TP53 LOH (35.3% versus 16.7%, P ¼ 0.621; 52.9% versus 33.3%, P ¼ 0.64, respectively; Figure 3C and D). In addition, the RB1 mutation was captured in CSF of four patients, all of whom carried TP53 LOH ( Figure 3E ).
EGFR T790M in CSF cfDNA
In CSF cfDNA, EGFR T790M was identified in 7 (7/23, 30.4%) patients with progression to TKI, and EGFR C797S was detected in 2 out of the 3 patients who had received AZD9291. In plasma, EGFR T790M was identified in 5 patients (5/23, 21.7%) ( Figure  2B ; supplementary Figure S1 , available at Annals of Oncology online). Among 13 patients who underwent rebiopsy of extracranial lesions, 6 patients were found to have EGFR T790M (6/13, 46.2%).
Dynamic changes of driver genes in CSF cfDNA throughout tailored therapy for LM In a case presentation (Figure 4) , the patient received AZD9291 for LM based on EGFR T790M detected in CSF. Her ECOG PS improved dramatically, partial response was confirmed on brain MRI, and a cytology response was identified in CSF. Moreover, the genetic profiles of CSF cfDNA showed dynamic changes of the driver genes.
After LM, 16 patients received AZD9291, and 15 of them obtained symptom improvement regardless of the status of EGFR T790M (Figure 3 ). There was no enough evidence of the therapeutic or prognostic results of other TKIs in current data, and we need to further explore the clinical role of MET CNVs.
Discussion
In this study, we involve a spatiotemporal review of LM in EGFRmutant NSCLC. The findings showed that EGFR-activating mutations in CSF cfDNA was consistent with those in primary tumors, and unique potential metastasis genes were identified in CSF cfDNA, suggesting the importance of CSF cfDNA as a liquid biopsy medium for LM.
Owing to the blood-brain barrier, CSF cfDNA is unable to circulate fully within the blood system, resulting in a limited amount of cfDNA from CNS being released to plasma; thus, plasma cannot fully represent the 'real world' of intercranial lesions [6] . In current cohort, we confirmed that gene alterations detected in CSF cfDNA were superior to those of the other two media. Tumor-derived DNA typically constitutes a small fraction of all cfDNA in plasma, while the proportion of such DNA in CSF is much higher due to the lower background of normal DNA. Similar to that, plasma cfDNA showed greater advantages than circulating tumor cells in providing the genetic landscape of primary and metastatic lesions [11] , while CSF cfDNA released from CNS lesions should be much more comprehensive than that of tumor cells found mainly in CSF precipitates. Moreover, CSF 100%  EGFR  T790M  C797S  ALK  MET  ERBB2  KRAS  RET  BRAF  TP53  MYC  FGFR1  CDKN2A  SMAD4  CDK6  POM121L12  CSMD3  CDK4  CCND1  STK11  FGF19  FGF3  KEAP1  BRCA1  RB1  NTRK1  SPTA1  AKT1  APC  PIK3R1  OR6F1  FGF4  NOTCH1  OR4A15  GATA3  FGFR3  OR4C6  OR5L2  KDM5A  MTOR  SOX2  GFRAL  CTNNB1  THSD7A  PTEN  ARID1A  SPOP  ERBB3  NAV3  TNR  SNTG1   27%  8%  12%  50%  12%  15%  4%  19%  81%  62%  42%  42%  35%  31%  27%  23%  23%  23%  23%  19%  19%  19%  15%  15%  15%  15%  12%  12%  12%  12%  8%  8%  8%  8%  8%  8%  8%  8%  8%  8%  4%  4%  4%  4%  4%  4%  4%  4%  4%  4%   B40  B12  B36  B44  B16  B02  B33  B08  B30  B35  B39  B20  B10  B18  B34  B45  B32  B24  B01  B26  B37  B21  B06  B07  B41 cfDNA has a potential role in revealing dynamic changes of the tumor burden of LM throughout treatment, and further studies should be conducted to explore its roles in prediction and prognosis. Genomic instability processes at the chromosomal and mutational level could lead to the evolution of CNVs [12] . Unique CNVs were identified in CSF cfDNA in this study, indicating that CNVs may be products of tumor evolution or even key mutations that predominate in LM. Among them, MET copy number gain was the most clinically relevant CNV and was an important cause of acquired resistance of TKI [13, 14] . And it was recently reported to be associated with gefitinib resistance in EGFRmutated LM by the in vitro and in vivo experiments [14] , and it responded to the combination of EGFR-TKI and crizotinib in cell line and mouse models, suggesting that it could be one of the resistance mechanisms of LM, a finding of both the current data and previous study [14] . CNVs at certain combinations of gene loci would alter the gene expression of different pathways, which could result in selective advantages for metastases [15] , so we hypothesized that unique CNVs in CSF may be the key events of LM in the evolution of lung cancer.
TP53 LOH and RB1 loss were universally altered in classical SCLC, and key to SCLC transformation, another cause of EGFR-TKI resistance in lung adenocarcinoma [16] [17] [18] [19] . In the current cohort, TP53 LOH and RB1 loss were uniquely identified in CSF cfDNA, as were other frequent alterations in SCLC including MYC and FGFR1, suggesting that CSF of LM patients harbored some of the molecular features of SCLC. TP53 and RB1 are tumor suppressor genes and their inactivation in neuroendocrine and alveolar type 2 cells of mice can lead to SCLC [18] . In addition, SCLC transformation would retain some of the characteristics of their adenocarcinoma origins [16] , as shown in a previous study where DNA analysis demonstrated a methylation pattern much closer to adenocarcinoma than SCLC in the cell lines of SCLC transformation. Although there was limited evidence of SCLC transformation in the morphology in current data, typical molecular features of SCLC in CSF might reveal the very early stage of SCLC transformation, which is not manifested as SCLC in the morphology but emerges as various molecular alterations that may play an important role in the progression of LM.
Continuing lower stimulation with TKIs in CNS may favor EGFR T790M mutation, the most common cause of acquired resistance [13] , but much lower frequencies of T790M in CSF or CNS lesions were described [7, 14, 20] . In the current study, T790M was identified in 30.4% patients in CSF cfDNA, which was higher than those in previous studies. This difference in the detection of T790M in CSF may be related to the samples and technology used in different studies, indicating the advantages of NGS with targeted ultra-deep sequencing in CSF cfDNA in current study. B40 B33 B20 B35 B12 B16 B36 B24 B08 B06 B45 B21 B18 B37 B30 B41 B07 B34 B01 B02 B32 B39 B26 B42 B43 B04 19delL858R 19delL858RL858R19del 19del19del 19del L858R19del L858R19del 19del 19del L858R 20ins 19del 19del 19del 19del 19del20ins19del 19del Figure 3 . TP53 LOH in CSF cfDNA. The criteria for TP53 LOH included AFs of TP53 greater than 50% (16 patients), AFs of TP53 1.4 times higher than those of EGFR (two patients), and TP53 copy number loss (one patient). LOH, loss of heterozygosity; Mut, mutation; Neg, negative; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; LM, leptomeningeal metastases; CSF, cerebrospinal fluid; PLA, plasma; Gef, gefitinib; Cri, crizotinib; Epi, epitinib; Erl, erlotinib; 9291, AZD9291; HD, high-dose; Bev, bevacizumab; Ico, icotinib; Afa, afatinib; NA, not available; Tis, tissue of rebiopsied lesions; 'both' denotes positive in the cfDNA of both CSF and plasma; CNVs, copy number variations. *P<0.001 TP53 LOH detected in CSF versus that in plasma; **P ¼0.162 concomitant resistance mutations detected in TP53 LOH patients versus those without TP53 LOH; # P ¼0.621 EGFR T790M detected in TP53 LOH patients versus those without TP53 LOH; ## P ¼0.64 MET CNVs detected in TP53 LOH patients versus those without TP53 LOH; analyzed by Fisher's exact test.
There were some limitations to this study. This was a retrospective study with small samples. As leptomeningeal lesions were invasive and difficult to access, we were unable to compare the genetic profiles between tissue and CSF.
In conclusion, CSF cfDNA provided comprehensive profiles of driver and resistance genes of LM, supporting the importance of CSF cfDNA as a liquid biopsy medium. EGFR T790M, CNVs of MET, KRAS, and ERBB2, and TP53 LOH may be the potential metastasis mechanisms of LM in EGFR-mutant NSCLC. Figure 4 . Case presentation. B12: during the therapy with gefitinib, the patient complained of dizziness, and brain MRI showed multiple leptomeningeal and brain metastases (a), and typical adenocarcinoma cells were found in CSF (1). EGFR 19 del and EGFR T790M were detected through NGS in CSF cfDNA. She then received AZD9291, and her symptoms alleviated dramatically within 2 weeks. Brain MRI (b) 1.5 months later showed an excellent partial response. Only a handful of suspicious tumor cells were found in the CSF several months later (2), while CSF cfDNA showed EGFR 19 del but without EGFR T790M, and the AFs of driver genes had decreased greatly. CSF, cerebrospinal fluid; CCRT, concurrent chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; NGS, next-generation sequencing; cfDNA, cell-free DNA; MRI, magnetic resonance imaging; AFs, allele fractions.
